Kiniksa Pharmaceuticals's total assets for Q1 2025 were $599.33M, an increase of 3.23% from the previous quarter. KNSA total liabilities were $141.84M for the fiscal quarter, a -0.20% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.